Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus

E Cañas; J Pachon; F Garcia-Pesquera; J R Castillo; P Viciana; J M Cisneros; M E Jimenez-Mejias

doi:10.1128/AAC.40.1.230

Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus

Antimicrob Agents Chemother. 1996 Jan;40(1):230-3. doi: 10.1128/AAC.40.1.230.

Authors

E Cañas¹, J Pachon, F Garcia-Pesquera, J R Castillo, P Viciana, J M Cisneros, M E Jimenez-Mejias

Affiliation

¹ Infectious Diseases Unit, Hospital Universitario Virgen del Rocio, Seville, Spain.

Abstract

Pharmacokinetic parameters of zidovudine (ZDV) were not altered in 16 patients receiving concomitant therapy with ZDV and trimethoprim-sulfamethoxazole by oral administration. ZDV areas under the concentration-time curves were (means +/- standard deviations) 1.80 +/- 0.70 and 1.69 +/- 0.64 micrograms.h/ml in the absence and presence of trimethoprim-sulfamethoxazole, respectively. ZDV clearances were 1.57 +/- 0.61 and 1.74 +/- 0.66 liters/h/kg, respectively.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antifungal Agents / pharmacokinetics*
Antiviral Agents / pharmacokinetics*
Drug Interactions
Female
HIV Infections / drug therapy*
HIV Infections / metabolism
Humans
Male
Middle Aged
Pneumonia, Pneumocystis / drug therapy*
Pneumonia, Pneumocystis / metabolism
Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology*
Zidovudine / pharmacokinetics*

Substances

Antifungal Agents
Antiviral Agents
Zidovudine
Trimethoprim, Sulfamethoxazole Drug Combination